Humana Inc. (NYSE:HUM) Shares Sold by Assetmark Inc.

Assetmark Inc. cut its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 17.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,114 shares of the insurance provider's stock after selling 2,609 shares during the period. Assetmark Inc.'s holdings in Humana were worth $3,074,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC grew its position in shares of Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Thrivent Financial for Lutherans boosted its stake in Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider's stock worth $190,145,000 after buying an additional 214,535 shares during the last quarter. Retirement Systems of Alabama increased its position in Humana by 735.9% during the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after purchasing an additional 192,801 shares during the last quarter. Pzena Investment Management LLC increased its holdings in shares of Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock worth $793,830,000 after buying an additional 187,903 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in Humana during the third quarter worth $50,102,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Remove Ads

Humana Price Performance

Shares of HUM stock traded down $8.35 during mid-day trading on Monday, reaching $251.41. The stock had a trading volume of 2,108,404 shares, compared to its average volume of 1,683,051. The company has a market cap of $30.33 billion, a P/E ratio of 25.27, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The business has a 50-day simple moving average of $271.80 and a 200 day simple moving average of $283.10. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.41%. Humana's payout ratio is currently 35.58%.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HUM. JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 15th. StockNews.com downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Barclays raised their price target on Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.